Log In
Print
BCIQ
Print
Print this Print this
 

daclatasvir (BMS-790052)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionSelective HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 and 4 infection in treatment-naïve patients; Treat chronic HCV genotype 1 infection; Treat chronic HCV genotype 1, 2 and 3 infection in treatment-naïve patients; Treat chronic HCV infection; Treat HCV genotype 1 infection; Treat HCV genotype 1 infection in patients who failed previous therapy; Treat HCV genotype 1 infection in treatment-naïve patients; Treat HCV genotype 1b infection; Treat HCV infection in patients with decompensated liver disease; Treat HCV infection in patients with decompensated liver disease, including HCV genotypes 1, 2, 3 and 4 infection; Treat non-cirrhotic, treatment-naïve patients with chronic HCV genotype 1 infection
Regulatory Designation

U.S. - Breakthrough Therapy (Treat HCV genotype 1b infection);
U.S. - Undisclosed Review (Treat HCV genotype 1b infection);
EU - Accelerated Assessment (Treat HCV infection in patients with decompensated liver disease, including HCV genotypes 1, 2, 3 and 4 infection);
Japan - Standard Review (Treat HCV genotype 1b infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today